Evidence map›Paper›PMID 41464778›Full record

ArticleJournal of clinical medicine2025

MLR and dMLR Predict Locoregional Control and Progression-Free Survival in Unresectable NSCLC Stage III Patients: Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

Alexandra Hochreiter, Markus Stana, Marisa Klebermass, Elvis Ruznic, Brane Grambozov, Josef Karner, Martin Heilmann, Danijela Minasch, Ayurzana Purevdorj, Georg Gruber and 3 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexandra HochreiterDepartment of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria.ORCID 0000-0003-4526-6091
Markus StanaDepartment of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria.ORCID 0000-0002-0155-0384
Marisa KlebermassKlinikum Ottakring, 1160 Vienna, Austria.
Elvis RuznicDepartment of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria.ORCID 0000-0001-7686-1008
Brane GrambozovDepartment of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria.ORCID 0000-0003-2454-7425
Josef KarnerDepartment of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria.
Martin HeilmannDepartment of Radiation Oncology, Comprehensive Cancer Centre, Medical University Vienna, 1090 Vienna, Austria.
Danijela MinaschDepartment of Radiation Oncology, Comprehensive Cancer Centre, Medical University Innsbruck, 6020 Innsbruck, Austria.
Ayurzana PurevdorjKlinikum Hietzing-Rosenhügel, 1130 Vienna, Austria.ORCID 0009-0002-2071-381X
Georg GruberOrdensklinikum, Department of Radiation Oncology, Johannes Kepler University, 4020 Linz, Austria.ORCID 0009-0004-8357-5439
Raphaela MoosbruggerDepartment of Pulmonology, Paracelsus Medical University, 5020 Salzburg, Austria.
Falk RöderDepartment of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria.
Franz ZehentmayrDepartment of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria.ORCID 0000-0001-5931-3907

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ALLSTARblood biomarkersdMLRdurvalumabMLRnon-small cell lung cancerRWD

Identifiers

PMID41464778
PMCPMC12734154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.